AI Adoption in Drug Regulatory Review Across the Lifecycle Transforms Decision-Making

Understanding the Drug Lifecycle and AI's Expanding Role

Pharmaceutical development follows a structured sequence of stages that begins with discovery and extends through preclinical testing, clinical trials, formal regulatory review, and ongoing post-marketing surveillance. Each phase generates vast quantities of complex data that traditional manual review methods struggle to process efficiently. Artificial intelligence, encompassing machine learning algorithms, natural language processing, and large language models, offers capabilities to automate summarization, detect patterns in safety signals, and integrate disparate evidence sources. Regulatory bodies are increasingly piloting these tools to address resource constraints while maintaining rigorous standards for safety, efficacy, and quality.

Key Findings from the Lee and Kim Analysis

Lee and Kim conducted a qualitative cross-comparative review of regulatory documents and policy publications from the United States, European Union, United Kingdom, and China. Their framework divided the drug lifecycle into five distinct stages and catalogued representative AI applications at each point. In the regulatory review stage specifically, agencies are deploying tools for automated document analysis, semantic knowledge extraction, and evidence synthesis. Adoption levels differ markedly by jurisdiction, driven by variations in policy frameworks, institutional governance capacity, and technical readiness. The authors note that while AI currently supports data-driven tasks, movement toward fully AI-enabled workflows remains gradual and cautious.

Regulatory Developments in the United States

The U.S. Food and Drug Administration has taken concrete steps to formalize AI use in drug-related submissions. In January 2025 the agency issued draft guidance titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. This document outlines expectations for sponsors regarding model credibility, context of use, and documentation when AI outputs inform assessments of safety, effectiveness, or quality. The guidance applies across nonclinical, clinical, manufacturing, and post-marketing phases, emphasizing risk-based approaches and ongoing monitoring. Additional FDA initiatives include early explorations of AI-assisted scientific review platforms designed to enhance consistency without replacing human oversight.

Further alignment emerged in January 2026 when the FDA collaborated with the European Medicines Agency on a set of ten guiding principles for good AI practice in drug development. These principles stress human-centric design, adherence to established standards, clear definition of context of use, and multidisciplinary expertise. They apply to evidence generation and monitoring across the entire medicines lifecycle, from early research through post-authorization activities.

Photo by Markus Winkler on Unsplash

European and International Perspectives

The European Medicines Agency has advanced its own framework through a multi-annual AI workplan and a reflection paper on the use of artificial intelligence in the medicinal product lifecycle. These documents address transparency, robustness, human oversight, and integration with existing good manufacturing and clinical practice requirements. Pilot projects have included AI-based knowledge-mining tools that assist reviewers in extracting relevant information from large regulatory submissions. The United Kingdom and China have launched parallel initiatives, including pilot programs focused on automated safety signal detection and policy development tailored to their respective regulatory environments. Disparities in maturity across these regions underscore the value of greater international coordination.

Persistent Challenges and Governance Considerations

Despite clear efficiency gains, the Lee and Kim study identifies recurring obstacles that regulators must navigate. Data bias can skew model outputs if training datasets underrepresent certain populations or therapeutic areas. Lack of explainability in complex algorithms raises questions about how reviewers should interpret and defend AI-assisted conclusions. Legal accountability remains ambiguous when automated systems contribute to approval or labeling decisions. Regulatory inconsistency between jurisdictions further complicates global development programs. The authors emphasize that structured human-AI governance frameworks, combined with targeted training for regulatory staff, are essential to mitigate overreliance on automated outputs and preserve legitimate decision-making authority.

Implications for Industry and Academic Research

Pharmaceutical sponsors stand to benefit from clearer regulatory expectations that encourage responsible innovation while protecting public health. Companies investing in validated AI systems for evidence generation may experience accelerated development timelines and more predictable review interactions. At the same time, the need for robust validation packages, data provenance documentation, and lifecycle monitoring creates new technical and compliance demands. Academic institutions are well positioned to contribute through interdisciplinary programs that combine regulatory science, data analytics, and pharmacology. Graduate training that incorporates AI literacy alongside traditional research methods can prepare the next generation of professionals for roles in regulatory affairs, pharmacovigilance, and health technology assessment.

Future Outlook and Pathways Forward

Global harmonization efforts, including continued dialogue between the FDA and EMA, are likely to shape the next phase of AI integration. Structured qualification pathways for AI methodologies, expanded real-world validation studies, and shared technical standards could reduce duplication and foster mutual recognition of assessments. Regulators will need sustained investment in workforce development to maintain critical oversight capacity as tools evolve. For the broader research community, the Lee and Kim analysis provides a timely benchmark against which future progress can be measured. Continued publication of transparent case studies and performance metrics will support evidence-based refinement of both policy and practice.

Photo by Numan Ali on Unsplash

Actionable Insights for Stakeholders

Organizations considering AI deployment in regulatory contexts should begin with clearly defined contexts of use and comprehensive risk assessments. Early engagement with regulatory authorities through pre-submission meetings can clarify expectations. Academic researchers may explore collaborative projects that generate independent validation data or develop explainability methods tailored to regulatory needs. Policymakers are encouraged to prioritize capacity-building initiatives that equip review teams with the skills required to evaluate AI outputs critically. These steps collectively support a measured transition toward more efficient, consistent, and accountable regulatory decision-making across the drug lifecycle.